Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016

Torsten Schlote; Ulrich Kellner

doi:10.1055/s-0033-1358214

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2016; 233(02): 203-219
DOI: 10.1055/s-0033-1358214

Augenheilkunde up2date

Georg Thieme Verlag KG Stuttgart · New York

Unerwünschte Arzneimittelwirkungen in der Augenheilkunde: Update 2015/2016

Adverse Drug Reactions in Ophthalmology – Update 2015/2016

Torsten Schlote

Tagesklinik Ambimed Basel

,

Ulrich Kellner

Zentrum für seltene Netzhauterkrankungen, AugenZentrum Siegburg

› Author Affiliations

Abstract

Unerwünschte Arzneimittelwirkungen (UAW) gehören zum Alltag jedes klinisch tätigen Ophthalmologen. Dies beschränkt sich keineswegs auf die konservative Augenheilkunde, sondern betrifft direkt auch operative Verfahren, wie die Kataraktoperation am Beispiel des intraoperativen Floppy-Iris-Syndroms (IFIS) verdeutlicht.

Full Text

References

Literatur
1 Schlote T, Kellner U. Nebenwirkungen von Medikamenten am Auge. Klimo-Refresher. Klin Monatsbl Augenheilkd 2009; 226: R173-R186
2 Schlote T, Kellner U. Unerwünschte Arzneimittelwirkungen in der Augenheilkunde – Update 2011/12. Klin Monatsbl Augenheilkd 2012; 229: 275-290
3 Vuori ML, Kaila T, Iisalo E et al. Systemic absorption and anticholinergic activity of topically applied tropicamide. J Ocul Pharmacol 1994; 10: 431-437
4 Bersani FS, Imperatori C, Prilutskaya M et al. Injecting eye-drops: a mini-review on the non-clinical use of tropicamide. Hum Psychopharmacol 2015; 30: 262-264
5 Raison-Peyron N, Du Thanh A, Demoly P et al. Long-lasting allergic contact blepharoconjunctivitis to phenylephrine eyedrops. Allergy 2009; 64: 657-658
6 Stavert B, McGuinness MB, Heper CA et al. Cardiovascular adverse effects of phenylephrine eyedrops: A systematic review and meta-analysis. JAMA Ophthalmol 2015; 133: 647-652
7 Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31: 664-673
8 Chang DF, Campbell JR, Colin J et al. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. Ophthalmology 2014; 121: 829-834
9 Casuccio A, Cillino G, Pavone C et al. Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome. J Cataract Refract Surg 2011; 37: 1447-1454
10 Schmitz K, Maier M, Clemens CR et al. Zuverlässigkeit und Sicherheit von intravitrealen Ozurdex-Injektionen. Die ZERO-Studie. Ophthalmologe 2014; 111: 44-52
11 Mazzarella S, Mateo C, Freixes S et al. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema. Ophthalmic Res 2015; 54: 143-149
12 Mathalone N, Arodi-Golan A, Sar S et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1435-1440
13 Tseng JJ, Vance SK, Della Torre KE et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012; 21: 241-247
14 Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: What is the evidence?. Retina 2015; 35: 841-858
15 Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther 2015; 31: 2-10
16 Narayanaswamy A, Neog A, Baskaran M et al. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 2007; 55: 127-131
17 Marmor MF, Kellner U, Lai TY et al. 2016 Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2016; [in press]
18 Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453-1460
19 Lee Y, Vinayagamoorthy N, Han K et al. Polymorphisms of cytochrome P450 2D6 are associated with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015; Aug 28. [Epub ahead of print]
20 Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122: 110-116
21 Leung LS, Neal JW, Wakelee HA et al. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 2015; 160: 799-805
22 Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 2014; 132: 1105-1112
23 Kellner S, Weinitz S, Farmand G et al. Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation. Br J Ophthalmol 2014; 98: 200-206
24 Liu L, Cuthbertson F. Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Case Rep Med 2012; 2012: 134636
25 Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 2013; 80: 139-144
26 Zarbin MA, Jampol LM, Jager RD et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 2013; 120: 1432-1439
27 Georgakopoulos CD, Makri OE, Vasilakis P et al. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012; 95: 233-236
28 Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond) 2013; 27: 102-104
29 Crabtree DV, Ojima I, Geng X et al. Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. Bioorg Med Chem 2001; 9: 1967-1976
30 Splinter MY. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults. J Cent Nerv Syst Dis 2013; 5: 31-41
31 Garin Shkolnik T, Feuerman H, Didkovsky E et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol 2014; 150: 984-989
32 Kawazoe Y, Sugita S, Yamada Y et al. Psoriasis triggered by infliximab in a patient with Behçetʼs disease. Jpn J Ophthalmol 2013; 57: 95-97
33 Tarkiainen M, Tynjälä P, Vähäsalo P et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford) 2015; 54: 1170-1176
34 Zamvar U, Dhillon B. Postoperative IOP prophylaxis practice following uncomplicated cataract surgery: a UK-wide consultant survey. BMC Ophthalmol 2005; 5: 24
35 Gallerani M, Manzoli N, Fellin R et al. Anaphylactic shock and acute pulmonary edema after a single oral dose of acetazolamide. Am J Emerg Med 2002; 20: 371-372
36 Zimmermann S, Achenbach S, Wolf M et al. Recurrent shock and pulmonary edema due to acetazolamide medication after cataract surgery. Heart Lung 2014; 43: 124-126
37 Choksi V, Hughes M, Selwa L et al. Transient neurologic deficit after acetazolamide challenge for computed tomography perfusion imaging. J Comput Assist Tomogr 2005; 29: 278-280
38 Parthasarathi S, Myint K, Singh G et al. Bilateral acetazolamide-induced choroidal effusion following cataract surgery. Eye (Lond) 2007; 21: 870-872
39 Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 2007; 18: 129-133
40 Mancino R, Varesi C, Cerulli A et al. Acute bilateral angle-closure glaucoma and choroidal effusion associated with acetazolamide administration after cataract surgery. J Cataract Refract Surg 2011; 37: 415-417
41 Malagola R, Arrico L, Giannotti R et al. Acetazolamide-induced cilio-choroidal effusion after cataract surgery: unusual posterior involvement. Drug Des Devel Ther 2013; 7: 33-36
42 De Rojas V, González-López F, Baviera J. Acetazolamide-induced bilateral choroidal effusion following insertion of a phakic implantable collamer lens. J Refract Surg 2013; 29: 570-572